Resiquimod (Standard)

Resiquimod (Standard) is the analytical standard of Resiquimod. This product is intended for research and analytical applications. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.

Product Specifications

CAS Number

[144875-48-9]

UNSPSC

12352100

Target

HCV; Reference Standards; Toll-like Receptor (TLR)

Related Pathways

Anti-infection; Immunology/Inflammation; Others

Field of Research

Inflammation/Immunology; Cancer

Smiles

OC(C)(C)CN1C(COCC)=NC2=C1C3=CC=CC=C3N=C2N

Molecular Formula

C17H22N4O2

Molecular Weight

314.39

References & Citations

[1]Sachan S, et al. Adjuvant potential of resiquimod with inactivated Newcastle disease vaccine and its mechanism of action in chicken. Vaccine. 2015 Aug 26;33 (36) :4526-32.|[2]Brugnolo F, et al. The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. J Allergy Clin Immunol. 2003 Feb;111 (2) :380-8.|[3]Zhou ZX, et al. Immune effects of R848: evidences that suggest an essential role of TLR7/8-induced, Myd88- and NF-κB-dependent signaling in the antiviral immunity of Japanese flounder (Paralichthys olivaceus) . Dev Comp Immunol. 2015 Mar;49 (1) :113-20.|[4]Maki Yokogawa, et al. Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erythematosus. Arthritis Rheumatol. 2014 Mar;66 (3) :694-706. |[5]Manuel Keppler, et al. Imidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratio in vitro and in vivo. Front Immunol. 2023 Jun 20:14:1168252.